FinLab AG

  • WKN: 121806
  • ISIN: DE0001218063
  • Land: Deutschland

Nachricht vom 30.09.2021 | 14:00

FinLab AG: Half-year results as of 30/06/2021

DGAP-News: FinLab AG / Key word(s): Half Year Results
30.09.2021 / 14:00
The issuer is solely responsible for the content of this announcement.

Half-year results as of 30/06/2021

- Positive result for the period according to German Commercial Code (HGB)

- Net asset value (NAV) at EUR 37.73 per share

Frankfurt am Main, 30/09/2021 - FinLab AG (ISIN: DE0001218063, WKN: 121806, Ticker: A7A.GR) announces its half-year results as of 30/06/2021.

In the first half of 2021 FinLab generated earnings before taxes (EBT) according to German accounting standards HGB in the amount of EUR 3.0 million (H1 2020: EUR 0.4 million).
The increase in earnings mainly resulted from performance fees received in the amount of TEUR 3,162 (H1 2020:
EUR 0.00) and from the sale of financial assets that lead to gains of TEUR 939 (H1 2020: TEUR 31). With equity of TEUR 59,593 (31 December 2020: TEUR 56,563) and an equity ratio of 96%, FinLab AG continues to have a solid balance sheet.

FinLab's NAV per share as of 30 June 2021 is EUR 37.73 (31 December 2020: EUR 32.02). The increase in the NAV per share is mainly due to the development of the investment in the listed Heliad Equity Partners GmbH & Co. KGaA.

FinLab AG's half-year report is published at www.finlab.de in the Investor Relations section.

 

About FinLab AG:

Stock market listed company FinLab AG (WKN 121806 / ISIN DE0001218063 / ticker symbol: A7A) is one of the first and largest investors focused on the Financial Services Technologies ("FinTech") and blockchain sector in Europe. FinLab focus in this context is providing venture capital for start-ups. FinLab's aim is a long-term participation and ongoing support of its investments. FinLab in this regard supports its investments in their respective development phase with their network and know-how. In addition, FinLab acts as an asset manager and manages assets in the three-digit million-dollar range.

Press contact:
FinLab AG:
investor-relations@finlab.de
Phone: +49 69 719 12 80 0
www.finlab.de


 


30.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021